CERADON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERADON is an injectable small-molecule NDA approved by Takeda in 1988, representing a legacy therapeutic with over three decades of clinical use. The specific indication and mechanism of action are not publicly detailed in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect defensive commercial strategy and possible team restructuring or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CERADON offers limited career growth opportunities given zero linked job postings and approaching LOE status. Roles available are defensive in nature, focusing on market preservation, generic/competitor management, and potential product lifecycle transitions or discontinuation planning.
Brand ManagerField Sales Representative
Worked on CERADON at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.